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 To the Editor  
 
In their recent article Alcaino et colleagues report a beneficial effect of hyperuricaemia in 
patients with chronic heart failure towards prevention of oxidative stress and improved 
endothelium function.  The conclusions from this observational study in 38 patients with CHF 
are opposite to a substantial body of evidence.   Therefore, we would like to make up for the 
authors shortfall to discuss these discrepancies and put the findings in perspective to current 
data.  
 
Most importantly, based on the presented background the hypothesis of the study reveals a 
serious misconception of the character of hyperuricaemia in CHF pathophysiology. Several 
studies are cited to support the role of UA as antioxidant to prevent oxidative damage including 
endothelium dysfunction. All these studies, however, tested the impact of administration of 
exogenous uric acid not the impact of endogenous physiologically derived uric acid.  While 
exogenous uric acid may indeed function to scavenge free oxygen radicals, it is of utmost 
importance to appreciate the origin of elevated UA levels in CHF.  It has sufficiently been shown 
by direct assessment of xanthine oxidase XO [i] as well as indirectly from allopurinol therapy 
studies [ii] that elevated XO activity the predominant cause of hyperuricaemia in CHF.  
Importantly, the uric acid generating enzyme XO is one of the major sources of oxygen free 
radicals in human physiology.  In fact, as early as 1968 the cytosolic XO was the first 
documented biological generator of oxygen derived free radicals [iii].  It seems an indefensible 
hypothesis to suggest hyperuricaemia as an adaptive process in response to the increased 
ROS accumulation if the UA and ROS are generated in parallel by up-regulated XO.  Moreover, 
the suggestion that this process in CHF “is leading to a raise in ecSOD activity and thus 
preserving endothelial function” has clearly been disproved as SOD and endothelium 
dysfunction are decreased in CHF well in parallel to disease severity.  
 
The idea that elevated (endogenous) UA levels may exert a beneficial effect on endothelium 
function and prognosis as discussed by the authors is in contrast to a large number of studies 
on vascular function [i, ii, iv, v] and mortality [vi, vii, viii] in heart failure patients and several 
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 other cardiovascular diseases including stroke [ix], cardiovascular risk [x], hypertension and 
renal disease [xi] as well as in normal populations [xii, xiii, xiv, xv].  Any attempt to include a 
representative number of all papers that provide data and conclusions that are opposite to the 
paper by Alcaino et al. would be stopped short due to limitation of space.   
 
Similarly the interpretation of UA as a risk marker at early CHF but as beneficial factor at 
advanced stages does not withstand reality as studies show linear associations of UA with 
disease severity [iv, xvi, xvii], mortality and impaired vascular function [v].    
 
While the ongoing scientific discussion regarding the role of uric acid as active contributor vs 
passive marker is indeed ongoing, Alcaino et al slipped in the misinterpretation of the absence 
of evidence as evidence of absence: If previous studies using allopurinol treatment could not 
prove a detrimental effect of UA itself this may by no means allow to conclude for a 
compensatory (i.e. beneficial) role of uric acid. The references quoted by Alcaino et al in support 
of their view are at least in part [xviii, xix] neither stating nor intending this message.   In fact, a 
recent study to test the effect of UA lowering without XO inhibition using uricase has shown no 
effect on endothelial function [xx].   
 
Alcaino et al seemingly base their study on the theory by Reyes that diuretic dependent 
increase in UA conveys improved prognosis in cardiovascular patients [xxi].  Whether the rise of 
uric acid caused by diuretic treatment may exert beneficial effect on antioxidant capacity is, 
however, the wrong question to ask and resembles the attempt to describe an elephant from 
looking at its tail.  The potential contribution of this particular cause to elevated UA cannot be 
looked at separately from other mechanisms to increase UA in CHF.  Elevated UA levels in CHF 
result likely from a combination of increased XO activity (i.e. overproduction, see above) and to 
some degree impaired excretion following impaired renal function and diuretic use. The isolated 
effect of the diuretic dependent UA increase in this context is, however, negligible as only the 
effect of total UA elevation may - or may not – be clinically relevant.  The theory by Reyes that 
diuretic dependent increase in UA conveys improved prognosis in cardiovascular patients has 
previously been challenged [xxii] an is convincingly refuted by a multitude of studies that show 
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 that (global) hyperuricaemia is a strong marker of disease severity and impaired prognosis (see 
above).  
 
Further, the assertion of the authors to address a previously not investigated association 
between UA, SOD activity and endothelium function is in negation of several papers that 
particularly evaluated these interactions [i, ii, v]. Notably, the findings on the impact of UA in 
CHF in these previous studies were opposite to the results by Alcaino. Unfortunately, these 
discrepancies were not discussed.   The authors comment that UA levels in their study were 
within normal limits in the majority of patients, however, not such data is presented. In the 
studied CHF patient group UA levels were abnormally elevated (7.3±2.3 mg/dl) and the 
comparison with the control subjects revealed significantly elevated UA levels in CHF patients 
(p<0.04).  Moreover, the references to underscore conformity with the other CHF populations 
are not applicable in this context [xxiii, xxiv]. Notable, elevated uric acid levels are a common 
finding in CHF with increasing UA in parallel to CHF severity [iv, xvi, xvii]. 
 
Despite the overwhelming evidence from previous studies against the conclusion by Alcaino et 
al, the current data need to be explained. On factor may rest with the small size of the study 
population and the statistical possibility of 5% to observe random associations. More 
importantly, the pre-specified selection of patients with significantly reduced endothelium 
function prevents a realistic reflection of the association over the normal pathophysiological 
range of patient. Looking at the limited part of the spectrum may results in a distorted 
association.     
 
It can be concluded that the findings and interpretation of the data by Alcaino are diametrically 
opposed to the current pathophysiological concepts.  The lack of discussing the discrepancy 
with the vast body of evidence against these data is dissatisfactory particularly given the nature 
of this study as a small observational study showing mere correlations that do not allow for 
causal interpretations.  The lack of relating the hypothesis and findings of the study to recent 
literature together with insufficient and in part incorrect referencing with previous studies 
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 highlight of course the responsibility of the Journal to ensure a thorough and high quality peer 
reviewing process.   
A rope is a rope is a rope. To recognise the shape and nature of the elephant might not be 
possible from the isolated gaze at its tail but requires an integrative inter-coordinated and 
repeatedly verified approach. 
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